The Effect Of Logotherapy-Based Psychoeducatıon Applıed To Famıly Members Of Indıvıduals Dıagnosıs Of Schızophrenıa

Brief summary (registry, in English)

Objective: This study aimed to determine the effects of logotherapy-based psychoeducation applied to family members of individuals diagnosed with schizophrenia on meaning in life, hope, and depression, and to examine experiences related to the psychoeducation process. Materials and Methods: Using a parallel convergent mixed methods design, the quantitative dimension of the study was designed as a randomized controlled trial, and the qualitative dimension was designed using a phenomenological method. The research was conducted between November 2023 and August 2025 with family members of individuals diagnosed with schizophrenia who were being followed up in the mental health and diseases outpatient clinics of a city hospital in Istanbul. A total of 40 family members were included in the study, 19 in the experimental group and 21 in the control group. Quantitative data were collected using the Demographic Information Form, Meaning in Life Scale, Herth Hope Scale, and Beck Depression Inventory, while qualitative data were collected using a Semi-Structured Interview Form. Pre-test measurements were performed on family members in both the experimental and control groups after randomization. Subsequently, individuals in the experimental group received an eight-session Logotherapy-Based Psychoeducation program individually online. Family members who completed the psychoeducation program underwent post-test measurements the following day, and qualitative data were collected through individual in-depth interviews. Family members in the control group received no intervention for eight weeks, after which post-test measurements were taken. Quantitative data were analyzed using the Wilcoxon signed-rank test, Mann Whitney U test, and t-test; qualitative data were analyzed using Colaizzi's phenomenological data analysis method.

What you commit to

• Study type: Interventional
• Participants enrolled: 42
• From 22 Dec 2023 to the primary completion date, 15 Jun 2025
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.